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This study aimed at investigating whether one of the key deficits in Attention Deficit Hyperactivity
Disorder (ADHD), slow response inhibition, predicted the response to methylphenidate (MPH)
treatment. In order to address this issue, we used Stop Signal Reaction Times (SSRTs) measured
at baseline in 20 medication-naïve boys with ADHD as predictor, and parent and teacher ratings
that were collected during a double-blind, placebo-controlled titration trial of MPH in the same
group as outcome measures. Parent and teacher ratings were collected on primary scales,
measuring ADHD symptoms, and secondary scales, measuring oppositional and disruptive
behaviour. Placebo response and ADHD/Oppositional Defiant Disorder symptom severity at
baseline were controlled for in the analyses. The SSRT did not predict the MPH response as
measured by parent ratings, but it did predict the MPH response as measured by teacher ratings.
This effect was specific for the ADHD scales. The slower SSRTs were, the less children benefited
from MPH. Moreover, children with longer SSRTs needed higher doses of MPH for optimal
symptom relief than children with shorter SSRTs. These findings have implications for clinicians
who face the decision of which MPH dose to prescribe.
Keywords: Attention Deficit Hyperactivity Disorder; Inhibition; Medication; 
Methylphenidate; Response inhibition
Introduction
Attention Deficit Hyperactivity Disorder (ADHD) is a common behavioural
disorder characterised by symptoms of inattention, hyperactivity, and impulsivity
*Corresponding author. Psychology Department, University of Arizona, 1503 E. University Blvd.,
Tucson, AZ 85721, USA. Email: ascheres@u.arizona.edu
D
o
w
n
lo
ad
ed
 B
y:
 [
Vr
ij
e 
Un
iv
er
si
te
it
, 
Li
br
ar
y]
 A
t:
 1
3:
04
 9
 D
ec
em
be
r 
20
10
94 A. Scheres et al.
(American Psychiatric Association, 1994). A deficit in inhibitory control has been
proposed to be the key executive function that is impaired in ADHD, which in turn
leads to other executive function deficits (Barkley, 1997). Two meta-analyses on
studies that have used the Stop Paradigm to measure inhibitory control show that,
indeed, children and adults with ADHD suffer from slow response inhibition (long
Stop Signal Reaction Times [SSRTs]) measured with the Stop Paradigm (Lijffijt,
Kenemans, Verbaten, & van Engeland, 2005; Oosterlaan, Logan, & Sergeant,
1998). It should be noted, however, that effect sizes are modest: d = 0.64
(Oosterlaan et al., 1998), d = 0.58 (Lijffijt et al., 2005), and d = 0.68 for the inatten-
tive type and 0.86 for the combined type (Willcutt, Dole, Nigg, Faraone, &
Pennington, 2005). Recent research has indicated that poor response inhibition is
not the only underlying mechanism involved in symptoms of ADHD. In a study that
compared the Stop Paradigm and the Choice Delay Task (measuring delay aversion)
in children with ADHD, it was shown that performance on both tasks explained
significant proportions of the variance in ADHD symptoms, and that performance
on these tasks did not correlate (Solanto et al., 2001). This finding led Sonuga-
Barke (2002) to propose a dual-pathway model for ADHD, suggesting that there are
at least two independent pathways leading to symptoms of ADHD: an executive
one, and a motivational one. More recently, other researchers have also reported
that only a subset of children with ADHD suffer from poor inhibition (see Nigg,
Willcutt, Doyle, & Sonuga-Barke, 2005), and multiple candidate endophenotypes
have been proposed (Castellanos & Tannock, 2002).
Given that slow response inhibition appears to be one key factor associated with
symptoms of ADHD, it is surprising that relatively little research has focused on
the link between response inhibition and the beneficial effects of psychostimulant
drugs. Psychostimulant drugs improve symptoms of ADHD in the majority of chil-
dren with this disorder (e.g., Greenhill et al., 2001). It may be hypothesised that
one way in which methylphenidate (MPH) exerts its beneficial effects on ADHD
symptoms is by improving inhibitory control. A number of studies have examined
the effects of MPH on response inhibition in ADHD (Aron, Dowson, Sahakian, &
Robbins, 2003; Barkley, Murphy, O’Connell, & Connor, 2005; Bedard et al.,
2003; Boonstra, Kooij, Oosterlaan, Sergeant, & Buitelaar, 2005; Jonkman et al.,
1999; O’Driscoll et al., 2005; Overtoom et al., 2003; Ridderinkhof, Scheres,
Oosterlaan, & Sergeant, 2005; Scheres et al., 2003; Tannock, Schachar, Carr,
Chajczyk, & Logan, 1989; Tannock, Schachar, & Logan, 1995; Vaidya et al.,
1998; Van der Meere, Gunning, & Stemerdink, 1999). All but three of these
studies (Jonkman et al., 1999; Overtoom et al., 2003; Van der Meere et al., 1999)
found that MPH significantly improved response inhibition during MPH treat-
ment. Thus, research has shown that MPH not only alleviates symptoms of
ADHD, but also positively affects one key deficit of this disorder, slow response
inhibition.
Another potential link between response inhibition and MPH, that of a predictive
association between response inhibition and MPH response as measured by
symptom improvement, has not so far been investigated. This is somewhat
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surprising, since a substantial body of research has focused on identifying predictors
for MPH response. The following factors have been identified as predicting a
positive response to MPH: higher levels of inattentive behaviour (Buitelaar, Van der
Gaag, Swaab-Barneveld, & Kuiper, 1995; Taylor et al., 1987; Thomson & Varley,
1998), higher levels of hyperactive behaviour (Barkley, 1976; Thomson & Varley,
1998; Taylor et al., 1987), lower overall severity of the disorder (Buitelaar et al.,
1995), poor performance on tests of attention and concentration (Barkley, 1976),
younger age (Taylor et al., 1987), high IQ (Buitelaar et al., 1995), presence of a
neurological disorder such as seizures (Thomson & Varley, 1998), positive parent
cognitions (Hoza et al., 2000), being male (Handen, Janosky, McAuliffe, Breaux, &
Feldman, 1994), higher socio-economic status (Handen et al., 1994), and having
the 10-repeat DAT1 allele (Kirley et al., 2003). Thus, poor performance on some
cognitive tasks (mainly measuring attention and concentration) has been identified
as a predictor, but to our knowledge nobody has studied whether performance on a
response inhibition task predicts MPH response.
Because poor response inhibition is a key feature of ADHD, and because response
inhibition can be ameliorated with MPH, it may be hypothesised that the ability to
inhibit responses is predictive of how well someone will respond to medication in
terms of symptom improvement. Therefore, our aim was to investigate whether
response inhibition, as measured with the most reliable dependent variable of the
Stop Paradigm (Logan, 1994; Logan & Cowan, 1984; Logan, Schachar, & Tannock,
1997)—SSRT—predicts the extent of symptom improvement during MPH treat-
ment in children with ADHD. Although group findings of medication trials indicate
that MPH has a positive effect on ADHD symptoms, and that higher doses work
better, the optimal dose is highly idiosyncratic (Rapport & Denny, 2000; Rapport
et al., 1987; Swanson, McBurnett, Christian, & Wigal, 1995). Therefore, group find-
ings are only of limited value to a clinician when facing the decision whether or not
to prescribe MPH, and, if prescribed, which dose to prescribe to an individual with
ADHD. For this reason, it is helpful to identify predictors, so that clinicians can
estimate the likelihood of an individual with specific characteristics to respond well to
medication, and, if this likelihood is high, which dose will most probably be optimal
for this individual.
We addressed this issue using SSRT as a predictor, and parent and teacher ratings
as outcome measures. SSRTs were collected during a baseline assessment in a
medication-naïve group of children with ADHD (Scheres et al., 2004), and parent
and teacher ratings were collected during a double-blind, placebo-controlled
titration trial of MPH in the same group (Scheres et al., 2003). In order to examine
whether the SSRT predicted the MPH response in terms of ADHD symptoms
specifically, or whether it also predicted improvement in behaviour not directly
related to ADHD, we included the Conners, Loney, and Milich (CLAM)
Inattention/Overactivity Scale (Loney & Milich, 1982; Pelham, Milich, Murphy, &
Murphy, 1989; Swanson, 1992) and the McBurnett, Swanson, Kotkin, Atkins, M-
Flynn, and Pelham (McSKAMP) Attention Index (Wigal et al., 1998) as primary
ADHD outcome measures, and the CLAM Aggression/Defiance Scale and the
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McSKAMP Deportment Index as secondary outcome measures related to
oppositional behaviour and disruption.
Methods
This study was approved by the Institutional Review Boards of the University of
Amsterdam and the three participating clinics.
Participants
Children were referred by paediatricians and child psychiatrists at three Dutch clinics.
These children were all identified as meeting the DSM-IV criteria (American
Psychiatric Association, 1994) for ADHD by the physician and/or a multidisciplinary
team of professionals, and advised to start treatment with MPH. All children were
medication-naïve. Twenty-three boys with ADHD in the age range of 6–12 years
participated in this study (Scheres et al., 2003). Twenty boys were included for data
analyses (see below), with a mean age of 8.8 years (SD = 1.7) and a mean IQ of 98.4
(SD = 15.3).
Group Selection and Characteristics
After establishment of the diagnosis by the physician, the parents and children
received a letter with information about the study and an informed-consent form. If
the parents and children decided to participate and they had signed the consent
forms, they were invited to participate in the study. Parents were administered the
Diagnostic Interview Schedule for Children—Parent version (DISC-IV) (Shaffer,
Fisher, Lucas, Dulcan, & Schwab-Stone, 2000). The section for Disruptive Behavior
Disorders was administered. For all participants, the DISC-IV confirmed the DSM-
IV diagnosis as established by the physician. According to the DISC-IV, 13 boys met
DSM-IV criteria for ADHD-combined type and seven boys for ADHD-inattentive
type. Ten boys also met the criteria for Oppositional Defiant Disorder.
Participants performed four subtests of the Revised Wechsler Intelligence Scale for
Children, while parents were interviewed. These subtests were Vocabulary,
Arithmetic, Block Design, and Picture Arrangement. The estimation of IQ as
obtained on these subtests correlates r = 0.93–0.95 with the full-scale IQ (Groth-
Marnat, 1997). Only when the DSM-IV criteria for ADHD were met, and when the
child’s IQ was above 70, could the child enter the study.
Parent and teacher ratings were taken at baseline, and were used as descriptive
measures. Scores were available for the following instruments: the Disruptive
Behavioral Disorder Rating Scale (Pelham, Gnagy, Greenslade, & Milich, 1992),
the DSM–IV screener (Hartman et al., 2001), the McSKAMP and the CLAM.
Scores on the ADHD scales confirmed the DISC-IV to the DISC-IV scores. This
sample demonstrated elevated scores on all ADHD scales as well as on some related
scales (see Table 1 and Figure 1).
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Figure 1. Average item scores for teacher and parent rating scales during baseline, placebo, and the most effective MPH dose.Stop Paradigm with Tracking Algorithm at Baseline
Before entering the double-blind placebo-controlled medication titration stage,
participants performed a battery of executive function tasks, among which was the
Stop Paradigm with tracking mechanism (for a detailed description of this task, see
Scheres et al., 2003, 2004). Briefly, the Stop Paradigm (Logan, 1994; Logan &
Cowan, 1984) involves two types of trials: go trials, and stop trials. Go trials were
airplanes presented for 1000 ms in the centre of the computer screen. A fixation
point (500 ms in duration) preceded the go stimulus. Subjects were required to press
the response button that corresponded to the direction in which the plane was
Table 1. Means and standard deviations for age, IQ, and baseline symptoms
Measure M SD
DBD parenta
Inattention 19.2b 3.8
Hyperactivity/impulsivity 17.8b 5.4
Oppositional Defiant Disorder 10.9b 5.1
Conduct Disorder 2.4 2.0
DBD teacher
Inattentionc 18.8b 5.8
Hyperactivity/impulsivityc 16.0b 7.3
Oppositional Defiant Disorderc 8.3 5.7
Conduct Disordera 2.8 3.6
DSM-IV screener parent
ADHDd 59.1b 7.2
Oppositional Defiant Disorderd 19.7 7.2
Conduct Disordera 40.4 5.7
Anxietya 44.1 4.0
Schizophreniaa 13.2 1.7
PDDa 28.8 4.4
Depressiona 22.0 2.4
DSM-IV screener teacher
ADHDc 58.1b 12.4
Oppositional Defiant Disordera 16.2 9.0
Conduct Disorderc 39.9 10.2
Anxietyc 43.4 7.0
Schizophreniac 13.0 2.7
PDDc 28.1 6.8
Depressionc 21.9 4.3
Note: DBD = Disruptive Behavior Disorder Rating Scale; DSM-IV = Diagnostic and Statistical 
Manual of Mental Disorders; PDD = Pervasive Developmental Disorder. an = 19. bAverage scale 
score is at or above the 95th percentile. cn = 20. dn = 18.
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pointing. The inter-stimulus interval was 1500 ms. The inter-trial interval was 3000
ms. Stop trials consisted of a go trial and a stop signal (a 1000 Hz tone, 50 ms in
duration), presented through earphones. The stop signal was usually presented
shortly after the airplane. Children were instructed not to press either button when
they heard the tone. The delay between the go and the stop signal varied. The longer
this delay, the harder it is to inhibit the response. Seventy-five per cent of the trials
were go trials, and 25% were stop trials.
The dependent variable that reflects the latency of the inhibitory process is the
SSRT. The SSRT cannot be observed because the response to a stop signal is a
covert one. Therefore, the SSRT is estimated. This can be done using the race model
(Logan & Cowan, 1984), which assumes that the go process and the stop process are
independent. The go stimulus triggers the go process, and the stop signal initiates the
stop process. The process that finishes first wins the race. If the go process wins the
race, the response is executed. If the stop process finishes first, the response is inhib-
ited. The outcome of the race depends on the speed and the variability of the go
process, the delay between go stimulus and stop signal, and the speed and the
variability of the stop process. The advantage of the Stop Paradigm with tracking
algorithm is that it achieves a success rate on inhibition trials of 0.5. Consequently,
the SSRT can be simply estimated by subtracting the mean delay from the mean
reaction time (see Logan et al., 1997). SSRTs as estimated with this procedure are
more reliable than SSRTs as estimated based on the Stop Paradigm with fixed
intervals (Band, Van der Molen, & Logan, 2003). Therefore, we focused on the
SSRT as obtained with the Stop Paradigm with tracking algorithm for this study.
Medication Titration
Within a week after the baseline assessment, participants started the titration stage. A
pseudo-randomised, multiple-blind, placebo-controlled crossover design was used in
which all participants received each of four treatment conditions: placebo, 5, 10, and
Figure 1. Average item scores for teacher and parent rating scales during baseline, placebo, and 
the most effective MPH dose
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20 mg of MPH (see Table 2). Medication and placebo were prepared by the hospital
pharmacy and packed in identical tablets (placebo tablets contained only a base gran-
ulate). The highest dose never exceeded 0.9 mg per kg body weight. Each treatment
condition was administered over 7 days, twice daily, at breakfast (around 7:30 a.m.)
and at lunch (around 12:30 p.m.). The order of the weeks was balanced using a Latin
square design. Within each week, all four treatment conditions were administered
and ordered such that one condition was never administered on two successive week-
days. Weekend doses were randomised by week; that is, the weekend dose was
constant within weekends. Medication compliance was verified throughout the medi-
cation period. Parents were carefully instructed about medication administration,
and they handed in empty medication boxes and took home new ones on a weekly
basis. Children did not receive any other form of treatment during the titration stage.
Parent and Teacher Observations during Titration
In order to measure medication effects on the child’s behaviour, parents and teachers
completed morning and afternoon rating scales during weekends at home and during
weekdays in school, respectively. The informants observed the child’s behaviour for
3.5 h, starting 1 h after administration, and rating scales were completed immediately
following the observation period. Parents were carefully instructed about the use of
the rating scales. One parent was selected to complete all rating scales. Teachers were
visited to carefully instruct them about the titration procedure and rating scale
completion. When possible, one teacher was selected to complete the rating scales.
The following rating scales were used: as primary ADHD outcome measures, we
used the CLAM Inattention/Overactivity (IO) Scale and the McSKAMP Attention
Index (AI) for parents and teachers. As secondary oppositional/disruptive outcome
measures, we used the CLAM Aggression Defiance (AD) Scale and the McSKAMP
Deportment Index (DI) for parents and teachers. All items were scored on a 4-point
scale, with higher scores reflecting higher severity of symptoms.
Statistical Analyses
Outliers and missing data.   Prior to data analyses, data for two children were
excluded due to extremely slow SSRTs. The SSRT of another child was missing due
Table 2. Medication design (mg of methylphenidate)
Saturday Sunday Monday Tuesday Wednesday Thursday Friday
Lead-in 0 5 10 20
Week A 0 0 0 5 10 20 0
Week B 5 5 5 10 20 0 5
Week C 10 10 10 20 0 5 10
Week D 20 20 20 0 5 10 20
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to technical failure. Therefore, statistical analyses were conducted with a sample of
20 boys with ADHD.
Analyses of variance.   As a first analysis, we investigated whether, on average,
children responded to MPH treatment as rated by teachers and parents. We
performed two analyses of variance (ANOVAs) (one for teacher ratings and one for
parent ratings) with Condition as within group factor. Condition had three levels in
this analysis: baseline, placebo, and the most effective dose (which could be 5, 10, or
20 mg, depending on the individual and on the informant). For each rating scale,
the most effective dose was defined as the dose that resulted in the lowest score on
that rating scale. Simple contrasts were used to examine whether symptoms as
observed during the most effective medication condition significantly differed from
symptoms during baseline and during placebo.
Stepwise regression.   Regression analyses were performed to measure whether the
SSRT at baseline predicted the response to MPH. Eight separate stepwise regression
analyses were performed for each scale per informant. Within informants, regression
analyses were performed for the CLAM IO Scale, the CLAM AD Scale, the
McSKAMP AI, and the McSKAMP DI. The dependent variable in each of these
analyses was the average item score on that scale during the most effective medica-
tion condition. For each rating scale, the most effective medication condition was
defined as the MPH dose that resulted in the lowest score on that rating scale. The
main predictor of interest was the SSRT at baseline. For each regression, the average
of baseline and placebo rating scale scores for that particular scale and informant
was entered as predictor at Step 1 in order to control for the confounding influence
of severity of symptoms at baseline and for placebo effects. The baseline SSRT was
entered as predictor at Step 2. With these stepwise regression analyses, we investi-
gated whether the baseline SSRT predicted the MPH response while controlling for
behavioural ratings during baseline and placebo (see Table 3).
Exploratory inspection of the SSRT–optimal dose relationship.   For those outcome
measures that were predicted significantly by SSRT, we were interested in exploring
whether there was also a relation between SSRT at baseline and which dose was the
most effective medication condition. To this end, we divided the group into three
subgroups: children for whom 20 mg, 10 mg, or 5 mg was the most effective dose,
respectively. ANOVA was used to compare optimal dose groups with SSRT as the
dependent variable.
Results
Analyses of variance
ANOVAs showed that, across subjects, symptoms of ADHD were reduced during the
most effective dose as compared with baseline and placebo (see Figure 1). Main effects
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of Condition were found for all four teacher rating scales, including the primary
ADHD scales (F(2,34) = 40.9, p < .001, η2 = .71 for the CLAM IO scale; F(2,34) =
23.8, p < .001, η2 = .58 for the McSKAMP AI) and the secondary oppositional/
disruptive scales (F(2,34) = 6.8, p < .01, η2 = .29 for the CLAM AD Scale; F(2,34)
= 12.8, p < .001, η2 = .43 for the McSKAMP DI). Main effects of Condition were
also found for all four parent rating scales, including the primary ADHD scales
(F(2,36)=27.1, p < .001, η2 = .60 for the CLAM IO Scale; F(2,36) = 14.9, p < .001,
η2 = .45 for the McSKAMP AI) and the secondary oppositional/disruptive scales
(F(2,36) = 11.4, p < .001, η2 = .39 for the CLAM AD Scale; F(2,36) = 18.7, p <
.001, η2 = .51 for the McSKAMP DI). Contrast tests showed that scores during the
most effective medication dose differed significantly from scores during baseline (all
F values > 9.0; all η2 values > .35) and placebo (all F values > 9.6; all η2 values > .36).
Stepwise Regression
Regression analyses showed that the SSRT accounted for significant proportions of
the variance in teacher-rated MPH response on the primary ADHD rating scales: 30%
for the CLAM IO Scale (p < .001) and 16% for the McSKAMP AI (p < .05). Note
that this effect was specific for the ADHD scales: the SSRT did not predict teacher-
rated MPH response on the oppositional/disruptive outcome measures (see Table 3
and Figures 2 and 3). The association between SSRT and teacher-rated ADHD
symptoms during the most effective dose was positive, indicating that, in terms of
ADHD symptoms, children with faster SSRTs at baseline improved more during the
optimal MPH dose than children with relatively slow SSRTs (see Figure 2).
Figure 2. Partial correlation plots, reflecting the association between the SSRT at baseline and ratings during the best medication condition on the primary ADHD outcome measures, after controlling for ratings at baseline and placebo.3 secondary oppositional/disruptiv  outcome measures, after controlling for r tings at aseline and placebo.The predictive power of the SSRT was specifically related to teacher-rated MPH
response, as no significant portion of the variance in parent-rated MPH response
was accounted for by the SSRT (see Table 3 and Figures 2 and 3).
Exploratory Inspection of the SSRT–optimal Dose Relationship
Since there was a significant association between the SSRT at baseline and the
response to MPH during the most effective medication condition for the teacher
CLAM IO Scale and the teacher McSKAMP AI, we explored whether there was
also a relation between the SSRT and which dose was the most effective medication
condition based on these ratings. SSRTs are plotted per optimal dose group in
Figure 4. Note that the SSRTs as displayed in this figure are corrected for teacher
ratings at baseline and placebo (entered as covariate), in order to control for a
potential difference between subgroups in baseline/placebo teacher ratings. Figure 4
shows that increases in optimal dose were associated with increases in SSRT, after
controlling for baseline and placebo teacher ratings. In other words, children for
whom the teacher determined higher doses to be most effective for ADHD
symptoms in school had longer SSRTs at baseline than children for whom teachers
determined that a lower dose was optimal.
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Figure 4. SSRTs at baseline plotted for each of the three optimal dose groups.Given the unequal and small sample sizes of these optimal dose groups, significant
effects were not really to be expected. However, a large effect was observed for
the CLAM IO Scale (F(2,20) = 3.2, p < .07, η2 = .29), with contrast analyses
showing a significant difference between SSRTs for the 5 mg optimal dose group
and the 10 mg optimal dose group (p < .05). The effect for the McSKAMP AI was
non-significant, but had a medium effect size (F(2,20) = 1.0, ns, η2 = .11).
Discussion
The goal of this study was to investigate whether the SSRT, a measure of inhibitory
control as determined at baseline using the Stop Paradigm, predicted the MPH
response. Teacher and parent ratings were used as outcome variables. Primary
outcome measures were ADHD rating scales, and secondary outcome measures were
oppositional/disruptive rating scales. Ratings as obtained during baseline and placebo
Figure 2. Partial correlation plots, reflecting the association between the SSRT at baseline and 
ratings during the best medication condition on the primary ADHD outcome measures, after 
controlling for ratings at baseline and placebo
D
o
w
n
lo
ad
ed
 B
y:
 [
Vr
ij
e 
Un
iv
er
si
te
it
, 
Li
br
ar
y]
 A
t:
 1
3:
04
 9
 D
ec
em
be
r 
20
10
104 A. Scheres et al.
Figure 3. Partial correlation plots, reflecting the association between the SSRT at baseline and 
ratings during the best medication condition on the secondary oppositional/disruptive outcome 
measures, after controlling for ratings at baseline and placebo
Figure 4. SSRTs at baseline plotted for each of the three optimal dose groups
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were controlled for in the analyses. We found that the SSRT predicted the MPH
response as rated by teachers on the primary ADHD scales, but not as rated by parents.
Before we discuss these findings, it should be noted that the main limitation of this
study is the small sample size. The findings need to be interpreted with that in mind.
For example, the small sample size did not allow us to investigate any other
potentially interesting predictors. Moreover, the lack of a significant association
between the SSRT at baseline and the MPH response as measured with parent
rating scales may have been due to low power (see later). Therefore, future work
with a larger sample will need to replicate the findings reported here.
The predictive association between the SSRT and the MPH response is poten-
tially interesting, since this may give clinicians a tool to work with when they have to
estimate the likelihood of an individual’s response to MPH, and when they have to
decide which dose to prescribe. This study showed that children with relatively poor
inhibitory control at baseline (showing slow SSRTs) have relatively high levels of
ADHD symptoms during the most effective medication condition. Thus, in terms of
symptoms of ADHD, children with relatively fast SSRTs improved more while on
the most effective MPH dose than children with relatively slow SSRTs. Importantly,
this effect was independent of severity of symptoms at baseline, and independent of
placebo response, and therefore could not be explained by more room for symptom
improvement in children with relatively slow SSRTs.
The SSRT predicted the MPH response as measured by teacher-rated ADHD
outcome measures (i.e., the McSKAMP AI and CLAM IO Scale, but not the
McSKAMP DI and CLAM AD Scale). The lack of an association with these
oppositional/disruptive scales may be meaningful in the sense that the SSRT may be
a MPH response predictor specifically related to symptoms of ADHD. However, this
may also have been due to restriction of range in the oppositional/disruptive scores,
especially for the CLAM AD Scale. Note that scores on this scale were below 1 even
at baseline and placebo. There was therefore not much room for improvement on
this scale. There was enough room for improvement on the McSKAMP DI,
however, and yet no significant association between the SSRT and the MPH
response on this scale was found.
The SSRT did not significantly predict the MPH response as measured by parent
ratings. This may be explained by the possibility that inhibitory control is a skill that
is required less to function well at home than to function well in the classroom.
Although the small sample size used here should temper any definite conclusion
about specificity of the association between the SSRT and teacher outcome
measures, the effect sizes for the parent-rated MPH response were small. Therefore,
it is unlikely that effects this small in size would become significant in a substantial
sample. This informant-specific finding is mirrored in previous studies establishing
that executive functioning measures relate to teacher ratings of ADHD, but not to
parent ratings. For example, Oosterlaan, Scheres, and Sergeant (2005) found that
only teacher ratings predicted performance on a number of executive functioning
measures including measures of planning and working memory. Riccio, Hynd,
Cohen, and Gonzalez (1993) found that teacher ratings of ADHD and other
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behavioural problems predicted performance on a measure of set-shifting, whereas
parent ratings failed to do so. Together with these earlier studies, the present study
fits with the finding that teachers, as opposed to children and parents, are the
optimal informants for ADHD symptoms (Loeber, Green, & Lahey, 1990; Loeber,
Green, Lahey, & Stouthamer-Loeber, 1989, 1991; Power et al., 1998).
Although the SSRT predicted significantly how much children’s ADHD
symptoms improved during the most effective MPH dose as measured by teacher
ratings, and effect sizes were large, an important question is whether this finding is
clinically relevant. Inspection of the individual teacher scale scores during the most
effective MPH dose shows that for most children (19 for the McSKAMP DI, 18 for
the McSKAMP AI, and all 20 for both CLAM Scales), symptoms were normalised
(average item scores between 0 and 1). Thus, although children with faster SSRTs
improved more than children with slower SSRTs during the most effective dose,
symptoms were within the normal range for virtually all children during the optimal
MPH dose. Therefore, the relation between the SSRT and the teacher-rated MPH
response may be only of limited clinical relevance.
The finding that children with longer SSRTs need higher doses for optimal
symptoms improvement may be a more clinically relevant one, as it can potentially
help in the decision related to which dose to prescribe. However, this finding needs
to be replicated in a larger sample before it can be interpreted as being reliable. The
fact that there was a significant difference for the SSRT between optimal dose
groups with such small subgroup sample sizes (for the CLAM IO Scale) was
surprising and a reflection of the large size of this effect.
In summary, this is the first study that reports on a significant association between
inhibitory control and the MPH response as measured with teacher-rated ADHD
scales. Moreover, the SSRT also had predictive value in terms of which MPH dose
would be optimal. Although this study suffered from a small sample size, effect sizes
reported here were large and, if replicated, the SSRT may be an important predictor
for MPH response, and for the optimal MPH dose in particular.
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